7.86
+1.95%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Hunan Hansen Pharmaceutical Co
Its shares trade on Shenzhen under the ticker 002412.SZ. It has been listed since 25 May 2010. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.04bn and net income of CN¥198.1m. At that date it held total assets of CN¥2.69bn and shareholders' equity of CN¥2.38bn.
Hunan Hansen Pharmaceutical Co. Ltd. engages in the research, development, manufacture, and sale of Chinese medicines. The company is headquartered in Yiyang, Hunan. The company went IPO on 2010-05-25. The Company’s main products include Simotang oral liquid, used for abdominal distention and phlegmatic abdominalgia; Yushangling capsules, used for injuries from falls; Yinxingye capsules, used for stroke and chest distress, as well as Suoquan capsules, used for kidney deficiency, among others. The firm mainly distributes its products in domestic markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 25 May 2010
- Employees
- 1,533
- Website
- hansenzy.com ↗
Leadership
Pay as last reported
- Mr. Zhengqing LiuChairman of the Board, President, since 2023CN¥223,300
- Mr. Jianghong DaiChief Financial Officer, Vice President, Secretary of the Board
- Mr. Lingsong AoVice President, DirectorCN¥131,000
- Mr. Jianjun FuVice President, Director, since 2014
- Ms. Aihua LiuVice President, since 2023CN¥129,500
- Mr. Zhijun LiuVice President, Chief Production Officer
- Mr. Hua YangVice President
- Mr. Gaoyun HuIndependent Director
- Mr. Bingyang LiuIndependent Director
- Mr. Jinsong XiaIndependent Director
- Ping ZhanIndependent DirectorCN¥50,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Hunan Hansen Pharmaceutical employs 1,533 full-time employees for research and development.
- Hunan Hansen's main products include Simotang oral liquid and Yushangling capsules.
- Hunan Hansen focuses on domestic market distribution for its pharmaceutical products.
Weaknesses
- Hunan Hansen's products are limited to Chinese medicine applications.
- Hunan Hansen has no international market presence beyond China.
- Hunan Hansen's business is concentrated in the domestic Chinese market.
Opportunities
- Hunan Hansen could expand into international markets for Chinese medicine products.
- Hunan Hansen may develop new products for stroke and chest distress treatments.
- Hunan Hansen can leverage its domestic market leadership in Chinese medicine.
Threats
- Hunan Hansen faces competition from other Chinese pharmaceutical companies.
- Hunan Hansen is vulnerable to regulatory changes in the Chinese healthcare sector.
- Hunan Hansen's reliance on domestic market could be affected by economic downturns.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.